The FDA grants priority review to Celgene's (CELG) NDA for the supplemental use of ABRAXANE...

|About: Celgene Corporation (CELG)|By:, SA News Editor

The FDA grants priority review to Celgene's (CELG) NDA for the supplemental use of ABRAXANE alongside gemcitabine for patients with advanced pancreatic cancer. (PR)